Lisa Casale, MD
Pulmonary Disease · Edison, NJNPI 1982625984
Payments from drug & device makers
Across 521 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Philips North America LLC$786
- Amgen$537
- Inspire Medical Systems, Inc.$450
- Mylan Specialty L.p.$394
- plus $2K from 30 others
What the payments were for
- Food & beverage$9,27399%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 164 | $3,116 |
| AstraZeneca | 75 | $1,730 |
| Philips North America LLC | 60 | $786 |
| Amgen | 30 | $537 |
| Inspire Medical Systems, Inc. | 7 | $450 |
| Mylan Specialty L.p. | 34 | $394 |
| Boehringer Ingelheim | 26 | $379 |
| Electromed, Inc. | 27 | $355 |
| Insmed, Inc. | 20 | $289 |
| Pulmonx Corporation | 3 | $131 |
| Regeneron Healthcare Solutions, Inc. | 9 | $130 |
| Sanofi | 8 | $112 |
| Grifols USA, LLC | 5 | $90 |
| E.r. Squibb & Sons, L.L.C. | 6 | $89 |
| Sunovion Pharmaceuticals Inc. | 6 | $85 |
| Merck | 5 | $67 |
| Verona Pharma, Inc. | 4 | $61 |
| Genentech USA, Inc. | 4 | $50 |
| CSL Behring | 2 | $49 |
| Mallinckrodt Hospital Products Inc. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| ANI Pharmaceuticals, Inc. | 2 | $44 |
| Johnson & Johnson | 3 | $40 |
| Pfizer | 2 | $31 |
| Baxter Healthcare | 1 | $27 |
| Shire North American Group Inc | 2 | $26 |
| Covidien LP | 1 | $22 |
| Lilly USA, LLC | 1 | $19 |
| United Therapeutics Corporation | 1 | $19 |
| Harmony Biosciences LLC | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $16 |
| Viatris Specialty LLC | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,335 in reported general payments places this provider in the 80th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 35 | $480,445 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 208 | $184,981 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 155 | $132,787 |
| TezspireTezepelumab-Ekko | 24 | $108,692 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 13 | $107,573 |
| NucalaMepolizumab | 26 | $101,527 |
| Spiriva RespimatTiotropium Bromide | 123 | $87,740 |
| Breo ElliptaFluticasone/Vilanterol | 78 | $54,154 |
| Dupixent SyringeDupilumab | 13 | $47,642 |
| AirsupraAlbuterol Sulfate/Budesonide | 52 | $25,774 |
| Arnuity ElliptaFluticasone Furoate | 35 | $16,070 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $14,523 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $11,828 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $9,867 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $9,372 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $379 | $568,185158 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $3,116 | $381,122395 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Airsupra, Symbicort, Pulmicort Flexhaler | $1,730 | $283,150274 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Edison
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.